Medical Professionals Reference (MPR)Baxfendy Earns FDA Nod as First-in-Class Hypertension Treatment

📋 Regulatory Action / Label Change

Baxfendy received FDA approval based on the phase 3 BaxHTN trial (N=794), in which baxdrostat 1mg and 2mg produced placebo-adjusted systolic BP reductions of 8.7 mmHg and 9.8 mmHg, respectively, at 12 weeks in adults with SBP ≥140 mmHg already on at least two antihypertensives including a diuretic.

Clinical Considerations

• Baxdrostat selectively inhibits aldosterone synthase, reducing plasma aldosterone and lowering BP through a mechanism distinct from existing antihypertensive classes
• Durable BP reduction was confirmed in an 8-week randomized withdrawal phase; patients rerandomized to placebo saw mean SBP rise of +1.4 mmHg versus continued reduction of -3.7 mmHg in the baxdrostat arm
• Hyperkalemia is the most common adverse reaction; hyponatremia may also occur; serum potassium and sodium monitoring is recommended before and periodically during treatment
• Eligibility criteria in BaxHTN required eGFR ≥45 mL/min/1.73m² and serum potassium 3.5–5.0 mEq/L; apply similar patient selection discipline in practice

Practice Applications

• Consider baxdrostat for adults with persistently uncontrolled hypertension on dual antihypertensive therapy including a diuretic
• Monitor serum potassium and sodium at baseline and throughout treatment; reduce to 1mg daily in patients at elevated risk for electrolyte disturbance
• Recognize aldosterone excess as a targetable mechanism in treatment-resistant hypertension, particularly in patients with mineralocorticoid-driven BP elevation